Boardroom Media (CEO News)
At CEO (Boardroom Media) we track over 1,000,000 startups and over 5,000,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top China based CEO’ operating in the Health Care space. If you think a CEO’ is missing from this list, feel free to contact our editor on [email protected].
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Steve Yang
Co-CEO of WuXi AppTec
Formerly Vice President and Head of Asia and Emerging Markets iMed at AstraZeneca; Vice President, Head of R&D Asia at Pfizer. Ph.D. in Pharmaceutical Chemistry from University of California, San Francisco.
Follow Steve Yang:
About WuXi AppTec: WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical.
Ge Li
Founder, Chairman and CEO of WuXi AppTec
Ge Li (李革) is the founder of WuXi AppTec, a Chinese company that provides compliant discovery, testing, and contract manufacturing services for pharmaceutical and medical device companies. The company was founded in 2000. Li holds a bachelor’s degree in chemistry from Peking University and a doctorate in organic chemistry from Columbia University.
Follow Ge Li:
About WuXi AppTec: WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical.
Edward Hu
Co-CEO of WuXi AppTec
Formerly Senior Vice President and Chief Operating Officer at Tanox, responsible for operations, finance, IT, project management and strategic planning. MBA and M.S. in Chemistry from Carnegie Mellon University.
Follow Edward Hu:
About WuXi AppTec, WuXi Healthcare Ventures: WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical.
Liangzhi Xie
President and CEO of Sino Biological
Dr. Xie obtained his doctor degree from the Biotechnology Process Engineering Center at Massachusetts Institute of Technology under the supervision of Prof. Daniel I.C. Wang. At MIT, Dr. Xie developed a stoichiometric model to optimize the design of mammalian cell culture medium and the control of the dynamic culture environment. In 1994, he was able to achieve a record cell density of 1.7 x 107 cells/ml and a record antibody titer of 2.4 gram/L. He then worked on viral vaccine process development and cGMP manufacturing for three US FDA approved products (Varicella® , Zostervax® , and ProQuad® ) at Merck Research Laboratory, Merck & Company. He also led the cell culture and viral vaccine process development and cGMP clinical production for Merck’s adenovirus based HIV vaccine and helped to develop by far the largest scale (2000L) of human viral vaccine process under serum-free condition in stirred-tank bioreactors. He is also the director and professor at the Cell Culture R&D center at the Peking Union Medical College since 2002.
Follow Liangzhi Xie:
About Sino Biological, Sinocelltech: Sino Biological is a specialist provider of protein, antibody and gene products.
John V. Oyler
CEO & Founder of BeiGene
John V. Oyler is our Chairman and Co-Founder, and has served as our Chief Executive Officer and a member of our Board of Directors since 2010. From 2005 to 2009, Mr. Oyler served as President and Chief Executive Officer of BioDuro, LLC, a drug discovery outsourcing company, which was acquired by Pharmaceutical Product Development Inc. in 2010. From 2002 to 2004, Mr. Oyler served as Chief Executive Officer of Galenea Corp., a biopharmaceutical company dedicated to the discovery of novel therapies for central nervous system diseases, which initially were developed at Massachusetts Institute of Technology. From 1997 to 2002, Mr. Oyler was a Founder and the President of Telephia, Inc. which was sold to The Nielsen Company in 2007. From 1997 to 1998, Mr. Oyler served as Co-Chief Executive Officer of Genta Incorporated (NASDAQ: GNTA), an oncology‑focused biopharmaceutical company. Mr. Oyler began his career as a management consultant at McKinsey & Company. Mr. Oyler received his B.S. from Massachusetts Institute of Technology and MBA from Stanford University.
Follow John V. Oyler:
About BeiGene: BeiGene is a life sciences, biotechnology company.
Xuefeng Yu
Co-Founder, Chairma, and CEO of CanSinoBIO
Dr. Yu received his Ph.D. in Microbiology from McGill University, Canada and has been appointed as Adjunct Professor of Pharmacology at Nankai University, Tianjin. Over the past few years, he has been awarded the title of “Leading Entrepreneur in innovation” by Ministry of Science and Technology, China, “Leading Entrepreneur of Beijing-Tianjin-Hebei BioPharmaceutical Industrial Demonstration Area”. He was also elected as one of the Tianjin “1000-Talents” and a Distinguished Expert. He has over 25 years of experience in the biopharmaceutical industry. Previously, he served as Director, Bioprocess R&D, and Corporate Platform Leader at Sanofi Pasteur Inc., one of the world’s largest vaccine suppliers. In that role, he led vaccine upstream process R&D in Canada and coordinated global activities across three R&D sites. He also played key roles in GMP production, new GMP facility validation, technology transfer and regulatory submission. Before joining Sanofi, he was a scientist at IBEX Technologies Inc., Canada, focusing on therapeutic enzyme products development.
Follow Xuefeng Yu:
About CanSinoBIO: Tianjin CanSino Biotechnology Inc. is a vaccine manufacturing facility.
Wang Tao
Founder, Chairman, and CEO of Ping An Good Doctor
Mr. Wang Tao, in 2004 joined the Alibaba Group, as Vice President Group Technology, founded Alibaba B2B, Taobao and Alipay technology and operations platform to build in 2007, was promoted to senior vice president of Alibaba Group and Ali Software CEO, successfully created China’s largest online software applications operate an open platform, “the father of Chinese software operational applications of” known, is an early “Fab Five,” one of Ma. Kingsoft previously served as CTO, and Lei Jun partners launched the first large-scale online game “JX online”, help Kingsoft was listed. His 16-year-old was admitted to Nanjing University computer science junior class, 20-year-old master’s Computer America, is a true prodigy. Master after graduation to join Microsoft headquarters in the United States to any development manager involved in the development of Microsoft windows media, Office and other products. 2013 was invited to join Ma Mingzhe, chairman of Ping An Group, he served as chairman and CEO of Ping An Health. Meanwhile, the Internet elite led the team to create a safe and healthy Internet Co., Ltd., and served as chairman and CEO, the use of a year to build a successful Chinese mobile medical largest APP – Ping good doctor. May 2016, Ping An good doctor officially announced the completion of $ 500 million A round of financing, the valuation of $ 3 billion. The financing and refresh the worldwide mobile medical start-ups and the single largest financing round A record two highest valuation. Wang Tao, with just two years, the good doctor has put peace into a mobile medical field the largest domestic company Unicorn. As of June 2016, Ping good doctor more than 80 million registered users, daily advisory capacity 250,000 times, ranking China Top50 most active App.
Follow Wang Tao:
About Ping An Good Doctor: Ping An Good Doctor is an Online-to-offline (O2O) healthcare servicing platform.
Liao Jieyuan
Founder & CEO of WeDoctor
EMBA, Guanghua School of Management, Peking University. A founder of China’s intelligent speech recognition industry, owns many patents. Was director of 863 Program (National High-tech R&D Program); prior to Guahao, Liao founded enterprise communications company China Gtel, once worth RMB 300 million.
Follow Liao Jieyuan:
About WeDoctor: WeDoctor is the world’s leading medical health technology platform.
Jun Wang
Founder & CEO of iCarbonX
Jun Wang is the founder and CEO of iCarbonX.In 1999, Jun Wang co-founded BGI, which is now widely recognized as one of world’s premier research facilities committed to excellence in genome sciences. During this time, Jun Wang managed three rounds of fund-raising (about 1B$ in total) at BGI, and acquired a U.S. public company: Complete Genomics. He was recognized with numerous awards and nominations, such as His Royal Highness Prince Foundation, and Fortune’s 40 under 40” by Fortune Magazine (2013)，Highly Cited Researchers 2015” by Thomson Reuters. Jun Wang received B.S. degree in artificial intelligence and Ph.D. in bioinformatics from Peking University.
Follow Jun Wang:
About iCarbonX: iCarbonX is a China-based artificial intelligence platform for health data company.
Youzhi Tong
Chief Executive Officer of Suzhou Kintor Pharmaceuticals
– Jointly founded Angion in US with rich entrepreneurial experience in technology companies. – More than 20 years of experience in R&D and management in biopharmaceutical area. – Led major national, provincial and municipal scientific research projects af
Follow Youzhi Tong:
About Suzhou Kintor Pharmaceuticals: Kintor is a pharmaceutical research company.
Samantha DU
Founder, CEO, & Chair of Zai Lab
Samantha Du is a Managing Director of Sequoia Capital China, responsible for healthcare investment. Dr. Du joined Hutchison China in June 2001 as Senior Vice President and has since led all aspects of development and management of the company’s R&D strategy. In 2002, she gained HWL’s approval for the establishment of Hutchison MediPharma and has built up the company to over 70 employees. Dr. Du has led the advancement of two Phase II US clinical trials; the establishment of a rich discovery portfolio in less than three years; and establishment of strategic alliances with world leading research institutions and companies. Dr. Du is a well-recognised leader in the R&D arena in China through her advisory roles to various government bodies. Dr. Du started her research career at Pfizer’s global R&D site in Connecticut, in the US, and led teams that delivered multiple INDs and NDAs for various anti-infective, cardiovascular, and metabolic medicines. Her last role at Pfizer was in the Global Strategic Operations Group, where she was in charge of licensing and related mergers and acquisitions activities in the metabolic disease area. Dr. Du received her Ph.D. in Biochemistry from the University of Cincinnati, in the US and her Bachelor’s and Master’s degrees in Molecular Biology and Chemistry from Jilin University, China. Prior to joining Sequoia China in 2012, Du founded and served as the Chief Executive Officer of Hutchinson MediPharma (HMP) for ten years. She was also the co-founder and Chief Scientific Officer of Hutchinson Chi-Med (LSE:HCM), a London AIM-listed company. She has built Hutchison Medipahram from scratch to a leading china based world renowned biotech company with rich product in both oncology and autoimmune. Under her leadership, the company has pioneered China’s FIH green channel, established first of its kind collaborations with multinational companies including JNJ, Lilly, PG etc. She was both on the planning committee and expert panel of the 12th five year state healthcare key projects. Prior to Hutchison, Du worked as a US-based executive of Pfizer’s global R&D and Metabolic business. She was involved in the development of multiple early and late stage product development, of which two were approved and launched globally. While at Pfizer, she served on FDA’s working committee. She is currently an Adjunct Professor at Fudan University’s School of Pharmacy and Chair of Pudong Drug Innovative Committee. Du is a recipient of Shanghai’s 2010 Magnolia award (an honorable citizenship award) and recipient of Shanghai’s thousand talent program. She was featured by many magazines and world renowned newspapers, including WSJ and Forbes and was on the cover of Forbe’s Asia in 2007.
Follow Samantha DU:
About Fudan University – School of Management, Sequoia Capital, Zai Lab: Zai Lab brings transformative medicines for cancer, autoimmune, and infectious diseases to patients in China and around the world.
Jinzi Wu
Founder & President , CEO of Ascletis
Jinzi Wu is the Founder ,President & CEO at Ascletis.
Follow Jinzi Wu:
About Ascletis, Gannex: Ascletis is a specialty therapeutics company developing therapeutics for the treatment of cancer and infectious diseases.
Zi Zhenjun
Founder & CEO of Venus MedTech
Zi Zhenjun Hangzhou Qiming Medical Devices Co., Ltd. founder, but also the founder and management partner of Reno Capital. Was co-founder and director of Xianjian Technology (01302, HK). He was also the first R & D manager for minimally invasive medical (00853, HK), as well as the deputy general manager and R & D manager of Veken Medical Devices. As China’s first generation of coronary artery PTCA balloon, coronary stent, aortic aneurysm stent graft, left ear ear occluder of the main designers, developed China’s first generation of congenital heart disease interventional occluder and lower chamber Venous thrombosis filter products, and the successful introduction of products to the international market, with more than 30 domestic and foreign patents, presided over and participated in the national and local governments at all levels a total of 25 research projects.
Follow Zi Zhenjun:
About Venus MedTech: Venus MedTech is an national high-tech industrial development zone.
Wei William Cao
Founder, Chairman and CEO of Gracell Biotechnologies
Follow Wei William Cao:
About Gracell Biotechnologies: Gracell Biotechnologies is a developer of cancer immune therapy designed to treat cancer.
Yuanwei Chen
Founder and Chief Executive Officer of Hinova Pharma
Yuanwei Chen is the founder and chief executive officer of Hinova Pharmaceuticals. Prior to this, Yuanwei spent more than 5 years working at Shanghai ChemPartner as general manager at Chengdu ChemPartner and VP of medicinal chemistry.
Follow Yuanwei Chen:
About Hinova Pharma: Hinova Pharma is a pharmaceutical company.
Sean Xu
CEO of Longrich
Sean Xu graduated from Oxford Brookes University as a business administration major in 2006. Now he is studying for his EMBA in China Europe International Business School. Also, he is a deputy to Changshu Municipal People’s Congress.He worked his way to the dizzy heights of CEO step by step from Longrich sales, finance, HR and risk control departments. And all Longrich staff is deeply impressed by his persistence, diligence and humility at work.In 2014, he carried out a series of changes related to delegation management, IT management, budget management and process optimization, which took Longrich operation results to new heights.Under the leadership of Sean Xu, Longrich will go farther and fly higher with faith, persistence, responsibility and gratitude in mind.
Follow Sean Xu:
About Longrich: Longrich is a Chinese cosmetics and health food producer.
Ye Yin
CEO of BGI Group
Ye Yin is CEO of BGI Genomics Co., Ltd. He joined BGI in 2002 and played an indispensable role in fighting against SARS, which has become his first achievement in the early career. He has been in charge of all the scientific collaboration business worldwide, from sales activities to market management, and to technical support in BGI. With BGI’s rapid development into the world-leading organization in genomic field and into diagnostics and agriculture industry, he contributed in the acquisition of Complete Genomics in 2013 and the smooth merge of CG with BGI. Ye has abundant experiences on massive lab production and quality management. He has successfully guided several international projects, like “1000 Plant and Animal Reference Genomes project”, “One Million Human Genomes re-sequencing project” and so on. He has several publications of genome research projects and genetic insights into medical research.
Follow Ye Yin:
About BGI Group: BGI Group is one of the world’s largest DNA sequencing service providers.
Racho Jordanov
Co-Founder, President and CEO of JHL Biotech
Racho Jordanov is a biotech pioneer with more than 30 years of experience building and leading manufacturing operations in development-stage and multi-national biopharmaceutical companies. Racho Jordanov started his career with Genentech, Inc. in 1981 in San Francisco, where he led the facility start-up and managed on-going commercial manufacturing of the first biotech products to be approved by FDA: insulin and rhGH. Over his 20-year career at Genentech Racho Jordanov was at the forefront of innovations in biopharmaceutical manufacturing, from introducing the first processes for monoclonal antibody (mAb) production, to establishing Genentech\’s outsourcing capabilities for drug substance, drug product and medical devices, to most recently starting-up new biomanufacturing facilities in the US and Singapore. In addition to Genentech, Racho Jordanov led North America manufacturing operations for Serono S.A. (now Merck Serono; Switzerland) and served as the Vice President of Manufacturing and Operations for two California-based biotech start-ups: Cholestech and Telios Pharmaceuticals. Racho Jordanov earned his B.S. in Chemical Engineering from the University of California, San Diego, and an M.B.A. from National University in San Diego. Racho Jordanov is a biotech pioneer with more than 30 years of experience building and leading manufacturing operations in development-stage and multi-national biopharmaceutical companies.
Follow Racho Jordanov:
About JHL Biotech: JHL Biotech is a start-up company founded in 2012 with a vision of making biopharmaceuticals affordable and accessible.
Raymond Stevens
Chief Executive Officer & Founder of ShouTi
Raymond Stevens is the Chief Executive Officer at ShouTi.
Follow Raymond Stevens:
About ShouTi: ShouTi specializes in the discovery and development of drugs against a type of targets called GPCR.
Yinxiang Wang
CEO and Chairman of Jacobio Pharmaceuticals
Yinxiang WANG graduated from the University of Arkansas for Medical Sciences in 1999, and served as a postdoctoral research fellow at the Department of Molecular Biophysics and Biochemistry of Yale University from 1999 to 2003.He returned to China in 2003 and founded Betta Pharmaceuticals. As the CEO and CSO (2003-2017) of Betta Pharmaceutiacals, YinxiangWang headed the research team, which developed Icotinib Hydrochloride (Conmana), a new molecular entity (NME) for lung cancer. This novel drug is the first small molecule anticancer drug that is completely developed in China and approved by CFDA in 2011. The project won the 1st prize of National Science and Technology Award, the gold medal of WIPO-SIPO Award in 2012 and 2014, and the 1st prize of Science and Technology Award in Zhejiang province. Betta went public at Shenzhen Exchange in 2016.Betta formed JV with Amgen (Amgen-Betta Pharmaceuticals) in 2013 and YinxiangWang served as GM (2013-2017).In 2015, he founded Jacobio Pharmaceuticals and ETown-Jacobio Biocapital in Beijing and serving as the Chairman. Jacobio is focused on innovative drug R&D, especially First-in-Class drugs, and ETown-Jacobio Biocapital as an angel fund to invest early stage R&D of innovative drugs. YinxiangWang is the Chairman, New Drug R&D Committee of China.Pharmaceutical Innovation and Research Development Association (PHIRDA); Associate Chairman,Oncology Drug Clinical Research Committee of Chinese Pharmaceutical Association.YinxiangWang was selected to be the national “Recruitment Program of Global Experts (1000-experts plan)”in 2012.YinxiangWang was selected to be the winner of 2017 CABS K.Fong Award in Life Sciences.
Follow Yinxiang Wang:
About Jacobio Pharmaceuticals: Jacobio Pharmaceuticals is a clinical-stage pharmaceutical company focusing on the development of innovative oncology and other therapies.
James Li
Co founder & CEO of JW Therapeutics
James Li was the founding General Manager for Amgen in China, where he led the company’s efforts in expanding its business into the Chinese market to help Chinese patients gain access to Amgen’s vital medicines. Prior to joining Amgen, James was a Partner at Kleiner Perkins Caufield & Byers life science practice, first in the US Pandemic Fund and later, in its China Fund. He successfully invested in early stage university spin out, growth stage companies and led a portfolio company went to public in 2010. From 1991 to 2006, James spent over 15 years with Merck Co. & Inc. where he held leadership positions with increasing responsibilities in clinical research, regulatory affairs, new product development and franchise management, both in the US and Asia Pacific/China. During his tenure, he was instrumental in obtaining regulatory approvals of Merck vaccines across Asia Pacific Region when the Vaccine Division started operations in the region, successfully built the foundations of Merck’s medical operations in China and drove the success of Merck’s largest franchise in Asia. James received his Medical Degree from Shanghai Medical University followed by a Master of Science degree in Microbiology from the University of Montana.
Follow James Li:
About JW Therapeutics: JW Therapeutics is a developer of cell-based therapy technologies created to revolutionize cancer treatment.
Hong Tan
Founder and Chief Executive Officer of ET Healthcare
Hong Tan, PhD, Founder and Chief Executive Officer, began his entrepreneurial career in 2000 when he founded Wave Crossing, a fiber optics company that developed a self-focus lens technology widely used in the optic fiber networks. In 2001, Hong founded FortéBio, where he led the creation of the Bio-layer Interferometry technology. Before starting his entrepreneurial endeavor, he worked for several data storage companies, including Iomega, Seagate, and Maxtor. Hong was responsible for the control system for the High Energy Imaging Device, a NASA space telescope project. He received Ph.D. and MSEE from Auburn University, BSEE from Xi’an Jiao Tong University, and EMBA from Cheung Kong Graduate School of Business.
Follow Hong Tan:
About ET Healthcare: ET Healthcare is an in vitro diagnostic technology company.
Chen Kuan
Founder and CEO of Infervision
Chen Kuan is founder and CEO at Infervision. He is a graduate of the University of Chicago, where he studied under four Nobel Prize winners, Gary Becker, Robert Fogel, James Heckmanm, and Lars Hansen. Chen also studied financial modeling and intelligent modeling in the Double Doctor Degrees Program of Economics and Finance. He founded the company in 2015.
Follow Chen Kuan:
About Infervision: Infervision is an AI high-tech company that uses deep learning technology and computer vision to help diagnose cancers.
Michael Xu
CEO of PegBio
Follow Michael Xu:
About PegBio: PegBio is a Chinese innovative drug developer.
Scott Liu
Co-Founder & CEO of Shanghai Henlius Biotech
Dr. Scott Liu, one of the global partners of Fosun International Limited, the Co-founder, President and CEO at Shanghai Henlius Biotech Inc., a global biopharmaceutical company focusing on the development, production and commercialization of high-quality and affordable biosimilar, biobetter and novel therapeutic monoclonal antibodies. Under his leadership, Henlius has become a leader of therapeutic monoclonal antibodies to treat a range of chronic and life-threatening diseases in China.Dr. Liu has more than 25 years of experience in biopharmaceutical R&D, manufacturing and quality management. Prior to joining Fosun Group in 2010, he has previously served several executive positions such as Vice President of R&D at United Biomedical, the Founding Director of the Biologics QC Department at Bristol-Myers Squibb (Syracuse, USA), and the Director of QAL (QC) at Amgen (Fremont, USA). Because of his extensive knowledge in quality and control of biologics, Dr. Liu had provided assistance to the CDE of CFDA in developing and implementing quality standards for biosimilars and novel biologics in China. Furthermore, Dr. Liu led the promotion of industry-wide adoption of single-use manufacturing technology to support the production of clinical and commercial monoclonal antibody therapeutics, and actively participated in the development of Technical Guidelines of Biosimilar Development and Evaluation to promote the innovation and globalization of the biopharmaceutical industry in China.Dr. Liu was the recipient of the the Bristol-Myers Squibb“Technical Operations Presidential Award”in 2004 and was recognized in 2013 as an expert of the “Thousand Talents Plan of Shanghai”. Dr. Liu received his Ph.D. degree in Biology from the Purdue University with postdoctoral training in Biology at Stanford University and studied business administration (iMBA courses) at the Syracuse University.
Follow Scott Liu:
About Shanghai Henlius Biotech: Shanghai Henlius Biotech is joint venture company that provides clinical-stage biopharmaceutical services.
Mark Engel
Founder,Chairman and CEO of Phagelux
Mark Engel is the Chairman and CEO at Phagelux
Follow Mark Engel:
About Excel PharmaStudies, Phagelux: Phagelux is a China-based company that utilizes phages to solve bacterial problems in multiple fields
Shiang Huang
Founder, CEO of Kindstar Global (Beijing) Medicine Technology
Shiang Huang (黄士昂) is the founder and chief executive officer of Kindstar Global (Beijing) Medicine Technology, a company providing advanced and specialized inspection services for hospitals. Huang is a director of Union Hospital affiliated with the TongJi Medical College of Huazhong University of Science and Technology and the Center for Stem Cell Research and Application. He is also a deputy director of the Institute of Hematology and director of the Hubei Key Laboratory of Biological Target Therapy.
Follow Shiang Huang:
About Kindstar Global (Beijing) Medicine Technology: Kindstar Global Medicine Technology is a Chinese high-tech enterprise that provides specialized inspection services for hospitals.
Frank Jiang
CEO of CStone Pharmaceuticals
Frank Jiang, MD, PhD joined CStone Pharmaceuticals in July, 2016 as its CEO. CStone Pharmaceuticals is a Chinese biotech company focused on addressing the most important patient needs in China and beyond. With immuno-oncology as CStone’s core therapeutic focus, the company strives to lead Chinese research to the global market through its world class R&D team, its innovative portfolio, and an open innovation strategy.
Follow Frank Jiang:
About CStone Pharmaceuticals, Sanofi China: CStone Pharmaceuticals is a bio-pharmaceutical company develops new treatments in a range of therapeutic areas.
Zheng Wei
Co-founder, CEO of Connect Biopharmaceuticals
Zheng Wei has been serving as our CEO since he co-founded the company in 2012. He has over 25 years of biopharmaceutical industry experience in the autoimmune diseases and inflammation therapeutic areas. Prior to co-founding Connect, Dr. Zheng was Director of Immunology at Arena Pharmaceuticals where he oversaw its immunology discovery programs. Prior to serving at Arena, Dr. Zheng was a founding scientist at ChemoCentryx. During his 10-year tenure at ChemoCentryx, he led the implementation of the company’s proprietary technology platform, and the discovery of drug candidates that entered Phase II and Phase III clinical trials for autoimmune disease indications including Crohn’s disease. His discovery research contributed significantly to the landmark strategic alliance between the company and GSK. Prior to joining ChemoCentryx, Dr. Zheng was a scientist at Glycomed (acquired by Ligand Pharmaceuticals). He also conducted immunology research at Stanford University School of Medicine. Dr. Zheng is an inventor of 16 issued patents and several pending patent applications on immunology related therapeutic agents and technologies. He received his Ph.D. in Biochemistry and Molecular Biology from the University of California at Davis. He has been selected to the National 1000Talents Plan of China.
Follow Zheng Wei:
About Connect Biopharmaceuticals, Northern Light Venture Capital: Connect Biopharma is a developer of novel immune modulators for the treatment of serious autoimmune diseases and inflammation.
Xin NI
Founder, Chairman and Chief Executive Officer of Eddingpharm (Cayman)
Xin Ni has extensive pharmaceutical industry experience and provides strong leadership and support for the commercialization of the EOC Pharma’s products in China. As the founder and controlling shareholder of Eddingpharm, Xin Ni has more than 22 years of in depth experience in the Chinese pharmaceutical industry. He currently serves as Chairman and CEO of Eddingpharm and Chairman of EOC Pharma. Over the past 17 years, Eddingpharm has been focused on introducing high quality prescription medicine to the Chinese market, providing patients with extensive treatment options and promoting important collaborations between Chinese KOLs and world leading medical research institutions.
Follow Xin NI:
About Eddingpharm (Cayman), EOC Pharma Group: Eddingpharm, a specialty pharmaceuticals company, focused on clinical nutrition, oncology, antibiotics, and respiratory system therapeutics.
Paul Shen
Co-Founder, Persident & CEO of Codoon
Bo Shen (申波) is the president and CEO of Codoon, a Chinese company that provides sports and wellness services through software and hardware solutions. Prior to that, he was engaged in technology research and development at Nokia, Siemens, Cisco, and more.
Follow Paul Shen:
About Codoon: Codoon is a sports and wellness service provider offering products that monitor users’ sport, sleeping and other physical conditions.
Ed Deng
Representative Director, CEO, and Founder of Health2Sync
Ed Deng is the Representative Director, CEO and Founder at Health2Sync.
Follow Ed Deng:
About Health2Sync: Health2Sync develops systems that transform smartphones into legacy medical devices and smart health monitoring machines.
Yusheng Han
CEO & Founder of Burning Rock Biotech
Yusheng Han is a Founder of Burning Rock, established Burning Rock in 2014, engaged in investment of medical fields; with successful experience in establishing and operating a start-up team; with six years of working experience in the field of life science.
Follow Yusheng Han:
About Burning Rock Biotech: Burning Rock Biotech focuses on providing individualized cancer treatment guidance for the patients.
Darren Ji
Founder and CEO of Elpiscience Biopharmaceuticals
Darren is co-founder and CEO of Elpiscience Biopharmaceuticals, Inc. He also serves as Venture Partner of Lilly Asia Ventures (LAV). Prior to that Darren was Global Vice President of Roche Partnering for Asia and Emerging Markets, as well as a leadership team member of Roche Partnering, Roche’s deal-making body that manages the company’s business development across the board including licensing and M&A. In this role Darren was responsible for driving the strategy and execution of partnering activities in the territory of Asia and Emerging Markets encompassing over 100 countries. During his tenure Darren championed and oversaw the closing of many key transactions between Roche and partners worldwide. He managed a global team and established a strong business network in key countries like China, Japan, Korea, Australia/New Zealand, Russia and Brazil. A repeat entrepreneur himself, Darren spent a long career at the Procter & Gamble Company with increasing responsibilities in drug R&D and business development. He co-founded and managed as CEO of PharmaLegacy Laboratories in Shanghai in 2008, which became a premium CRO providing high-quality drug discovery services to a global clientele until today. Darren has been a highly respected leader in global life sciences and a sought-after speaker in various business forums. He was also an avid community builder exemplified by completing one of the longest services as a board member of the BayHelix Group.
Follow Darren Ji:
About Elpiscience Biopharmaceuticals: Elpiscience is a clinical-stage biopharmaceutical company focused on innovating and developing next-generation immunotherapies.
Xia Yu
CEO & Chairman of Akeso Biopharma
Michelle Xia is a member of China’s 1000 Talents Program and the Innovative Talents by the Ministry of Science and Technology of China. Dr. Michelle Xia has over 20 years of experience in biopharmaceutical industry and academic research. Prior to founding Akeso Biopharma, she was Senior Vice President at Crown Bioscience, in charge of the Biologics Business Unit and Pfizer-Crown Asian Cancer Research Center. Prior to joining Crown Bioscience, Dr. Xia worked at PDL BioPharma (acquired by Abbott Labs) in the San Francisco Bay Area, one of the pioneer therapeutic antibody technology and drug development company, where she served as a core member in CMC project teams overseeing drug substance and product process development/manufacturing, technology transfer and FDA registration/IND enabling process. Prior to that, Dr. Xia worked at the CMC Process Development Department of Bayer in Berkeley. Her responsibilities there included building the Pathogen Safety facility at Bayer and managing viral safety evaluation/purification process validation for manufacturing biological products. Dr. Xia began her biopharmaceutical career at AXY Pharmaceuticals, which was acquired by Celera Genomics in 2001. During the six-year service with AXY/Celera, she played both scientific and managerial roles in drug discovery programs from target validation through IND enabling. Dr. Xia received her B. S. in Biochemistry from Zhongshan University in China and earned her Ph. D. in Molecular Biology and Microbiology from University of Newcastle in U.K. She did her postdoctoral research at University of Glasgow in U.K. and cancer immune therapy research at University of Louisville Medical School in the U.S.
Follow Xia Yu:
About Akeso Biopharma: Akeso Biopharma is a biopharmaceutical company committed to the discovery, development, and commercialization of therapies.
Liu Shuting
CEO of Supermonkey
Liu Shuting, CEO of SuperMonkey. Her nickname is Tiaotiao. Four years ago, her team consisting of six people created special pay-per-use fitness experience by a 24-hour container gym which provides appointment scheduling service.
Follow Liu Shuting:
About Supermonkey: Supermonkey develops and operates a mobile based application that offers fitness services.
Tao He
Founder & CEO of Miaoshou Doctor
Follow Tao He:
About Miaoshou Doctor: Miaoshou Doctor is a health care platform that provides communication services between doctors and patients.
Shirui Wang
Founder and CEO of Medlinker
Graduated from the West China School of Stomatology, Sichuan University, with an eight-year undergraduate, master’s and doctoral degree, and a research scholar at Harvard University. In 2014, Wang Shirui established the Medical Federation. In 2016 and 2018, he was twice selected as the “40 Business Elites under 40 in China” by the Chinese version of Fortune. In 2017 and 2018, he was selected as the “Top Ten New Economic Leaders of Sichuan” twice. In addition, Wang Shirui was also selected as the “Innovative Talent” announced by the Ministry of Science and Technology, and the National “Ten Thousand-Year Plan” Technology Innovation Leading Talent issued by the Organization Department of the CPC Central Committee.
Follow Shirui Wang:
About Medlinker: Medical Alliance is a post of physician social service platform.
Cheney Mao
Founder, Chairman, Chief Executive Officer, and Executive Director of Viva Biotech
Chen (Cheney) Mao is the Chairman, Chief Executive Officer, and an Executive Director of our Company. He is primarily responsible for the overall strategic planning and business development of the Group. Chen Mao has over 20 years of experience in the CRO industry. Chen Mao obtained his bachelor’s and master’s degree from Fudan University in the PRC, and obtained his Ph.D. degree in biochemistry from Cornell University in the U.S. After graduation, he served as a director of the Department of Structural Biology of Parker Hughes Institute. He also served as a reviewer on the U.S. National Institutes of Health Review Panel ZRG1 AARR-1(50) in relation to AIDS-related structural biology projects grants.
Follow Cheney Mao:
About Viva BioInnovator, Viva Biotech: Viva Biotech is a Healthcare Start Up Based In Shanghai.
Wenzhi Tian
Chairman, Founder, and CEO of ImmuneOnco Biopharma
Dr. Wenzhi Tian is the founder and Chairman of ImmuneOnco Biopharma Co., Ltd, a start-up company in China, with primary focus of its R&D on tumor immunotherapeutic drugs including checkpoint modulators and target-activated NK (TANK) products that will meet the unmet medical needs both in China and global market. Dr. Tian recently founded ImmuneOnco Biopharma in Zhangjiang Hi-tech Park dedicating to Research and Development of tumor immunotherapeutic drugs. Dr. Tian returned back to China in April of 2011 from ImClone Systems and established Huabo Biopharm Co., Ltd where he worked as Chief Executive Officer until April of 2015. Dr. Tian joined ImClone Systems as a Research Scientist in January of 2006 and resigned at the position of Principal Research Scientist in April of 2011. Prior to joining ImClone Systems, He was CSO of Aoko Biotechnology Ltd. from July of 2005 to December of 2005, where he was dedicated to developing therapeutic vaccine against HIV using yeast technology platform. Prior to joining Aoko Biotechnology, he was a Senior Research Associate from April of 2001 to Jun of 2005 at the division of immunology, department of medicine, Weill Medical College of Cornell University, with main focus on cloning and characterizing novel genes from B lymphocytes. From October of 1997 to April of 2001, he was a postdoctoral fellow at the division of molecular immunology, department of Rheumatology and Allergy & Immunology, North Shore University Hospital, NYU School of Medicine, dedicated to cloning and characterizing genes involved in Ig class switch recombination. Dr. Tian got his M.D. at Henan Medical University in 1987 and trained as a Ph.D. candidate from 1995 to 1997 at the department of Neurology and Clinical Immunology, Karolinska Institute, Huddinge Unversity Hospital, Huddinge, Sweden.
Follow Wenzhi Tian:
About ImmuneOnco Biopharma: ImmuneOnco is a tumor immunotherapy product developer engaged in the development and research of tumor immunotherapy products.
Carsten Lu
Founder, President and CEO of Adlai Nortye
Carsten Lu is the Founder, President and CEO of Adlai Nortye. Carsten has more than 15 years of experience in drug development and commercial operation. Carsten obtained an EMBA from CEIBS.
Follow Carsten Lu:
About Adlai Nortye: Adlai Nortye is a global clinical-stage biopharmaceutical company focused on innovative oncology drugs.
Steve Tan
CEO, Healthcare Software BU of United Imaging Healthcare
Follow Steve Tan:
About United Imaging Healthcare: United Imaging Healthcare develops and manufactures medical equipment and solutions.
Oscar Y. Wu
Managing Director/CEO of Ondal Medical Systems
Oscar Y. Wu is the managing director/CEO at Ondal Medical Systems Asia Pacific. He is responsible for overseeing operations for the China and Asia-Pacific region.
Follow Oscar Y. Wu:
About Ondal Medical Systems: Ondal Medical Systems designs, develops, and manufactures electromechanical equipment for use in operating rooms and intensive care units.
Du Bo
Co-Founder and CEO of GeneCast Biotechnology
Du Bo, Co-founder and CEO of Genecast (Beijing) Biotechnology Co., also a member of the Biotech Diagnosis Branch of China Medicinal Biotech Association. As one of the earliest developers to enter the field of NGS in China, Du Bo also co-founded China’s first NGS reagent manufacturer, Quest Genomics (Nanjing) Co., Ltd. Du Bo has accumulated rich experience in investment, pharmaceuticals, and second-generation sequencing, which renders him deep insights in corporate strategic development and management. He has frequently been invited to deliver speeches at conferences in biomedical field, and has won numerous awards, including the prestigious China Pharmaceutical Association’s Technology Progress Award. Du Bo graduated from the department of biology of Peking University.
Follow Du Bo:
About GeneCast Biotechnology: GeneCast Biotechnology is dedicated to improving cancer treatment through precision cancer diagnostics and companion diagnostics.
Xing Li
Founder and CEO of Deep Intelligent Pharma
With over 12 years’experience in drug development in Pfizer, Sanofi, and Johnson & Johnson, she founded the startup in October 2017, aiming to utilize most advanced AI technologies to empower and accelerate the whole drug discovery & development process. In Johnson & Johnson, she built a team of 31 staff from zero and implemented the first AI program in Johnson & Johnson Asia – regulatory document machine translation system – successfully. Xing got her master’s degree from Peking University Health Science Center in pharmaceutics.
Follow Xing Li:
About Deep Intelligent Pharma: Deep Intelligent Pharma is a Beijing based Healthcare company.
Sébastien Gaudin
CEO & Co-founder of The CareVoice
Upon graduating masters in pharmaceutical and commercial sciences in France, Sebastien worked in Sanofi, a world leading pharmaceutical company, for twelve years, where he held various positions in business development and marketing across multiple therapeutic areas and geographic markets. In 2011, he assumed a management position in Sanofi China focusing on diabetes portfolio and it was a great experience.
Follow Sébastien Gaudin:
About The CareVoice: The CareVoice is a health InsurTech company that provides a mobile-based data-driven SaaS platform.
Chen Yuanfei
Co-Founder & CEO of Elephant Medical
Graduated from Chinese Academy of Sciences with a Ph.D. degree in Computer Science and Technology，Executive Vice-president of Shandong Institute of Internet Things Technology（Jining Branch of Institute of Computing Technology，Chinese Academy of Sciences）,main research interest includes Pervasive Computing ,Embedded Technology, Virtualization Technology and so on.
Follow Chen Yuanfei:
About Elephant Medical: Mobile health solution provider based in Shanghai.
Martin Shen
CEO & Founder of Xingren Doctor
Follow Martin Shen:
About Xingren Doctor: Xingren Doctor is a company of group of doctors that manages patients and enables the public to understand health care.
Daixing Zhou
CEO of Berry Genomics
Dr. Daixing Zhou is the Chief Executive Officer of Berry Genomics Co., Ltd, located in Beijing, China. Prior to founding Berry Genomics, Dr. Zhou held multiple positions in the next generation sequencing industry, including the Leader of Market Development at Life Technologies Corp., the Head of Sequencing Sales at Illumina-Asia Pacific Japan, and the Director of Bioinformatics at Solexa Inc/Lynx Therapeutics. Dr. Zhou earned his Ph.D. from University of Maryland at Baltimore, and completed his postdoctoral training at Duke University.
Follow Daixing Zhou:
About Berry Genomics: Berry Genomics is a company specializing in developing and commercializing technologies for life sciences and clinical applications.
Zhixiong Liu
Chairman, CEO of 3Nod
Zhixiong Liu (刘志雄) is the chairman and CEO of Three Nod Group, a Chinese company that is focused on improving the quality of people’s lives through innovation, science, and technology. Liu holds an MBA from Royal Canadian University. He is the Chairman of the Board of Alavening.
Follow Zhixiong Liu:
About 3Nod: Three Nod Group focuses on improving the quality of people’s life through innovations in science and technology.
Jin Li
Founder, Chairman & CEO of HitGen
Dr. Li Jin has worked in the world’s top 500 companies, as the global compound science/computing science director of AstraZeneca, one of the world’s four largest pharmaceutical giants, and has more than 30 years of experience in drug development and scientific research management. Mainly responsible for computational science, computational chemistry, computational biology, and compound screening optimization. Dr. Li Jin graduated from the Department of Chemistry of Sichuan University and obtained a Ph.D. in polymer science from Aston University in the United Kingdom. He then engaged in postdoctoral research in biochemistry at the University of Manchester.
Follow Jin Li:
About HitGen: HitGen is provides biological reagents and services to support drug discovery research.
Ma Xuguang
Co-Founder and CEO of Medbanks
Ma Xuguang is the co-founder and CEO of Medbanks.
Follow Ma Xuguang:
About Medbanks: Medbanks is a database platform of clinical and professional medical services for clinical oncology.
Yeqing Zhu
CEO of New Horizon Health
Follow Yeqing Zhu:
About New Horizon Health: New Horizon Health is a bio-tech company focusing on early screening and genetic testing services for high-incidence cancer homes.
Wei Dong
CEO of EdiGene
Wei Dong has over 20 years of experience in drug development and corporate management in multinational companies . He holds a Ph.D. from Michigan State University, an MBA from Wharton , and a bachelor’s degree from Peking University. He used to be a senior consultant and manager of Deloitte Consulting, providing overall planning and consulting services for biotech companies and pharmaceutical companies. Formerly Senior Director of Johnson & Johnson Innovation Center, responsible for business operations and project management. He used to be Baxalta (later acquired by Shire , now affiliated to Takeda Pharmaceutical), senior director of clinical development in immunotherapy, and global development leader. He has experience in the development, clinical trials and management of a variety of innovative drugs, including Alzheimer’s disease drug development, cancer vaccine research and development, genetic disease orphan drug research and development.
Follow Wei Dong:
About EdiGene: EdiGene is a biotechnology company that develops genome editing technologies.
Bill Liang
CEO of CF PharmTech
Bill Liang is the CEO at CF PharmTech, Inc.
Follow Bill Liang:
About CF PharmTech: CF PharmTech is a specialty pharmaceutical company that develops and manufactures inhalation products.
Sun Fan
CEO, China of CXA Group
Follow Sun Fan:
About CXA Group: CXA is a AI-powered health and wellness eco-system.
John Gong
Chairman and CEO of 3D Medicines
Follow John Gong:
About 3D Medicines: 3D Medicines mission is to improve people’s health through cancer personalized diagnostics and treatment.
Simon Shung
Founder and Chairman, Co-CEO of 3D Medicines
Follow Simon Shung:
About 3D Medicines: 3D Medicines mission is to improve people’s health through cancer personalized diagnostics and treatment.
Menge Cheng
Co-CEO of Mindray Medical International
Menge Cheng is Co-CEO at Mindray Medical International.
Follow Menge Cheng:
About Mindray Medical International: Mindray Medical International Limited is China’s largest medical equipment manufacturer, developing, manufacturing, and marketing.
Chengbin Wu
CEO of EpimAb Biotherapeutics
Dr. Chengbin Wu is the founder and Chief Executive Officer of EpimAb Biotherapeutics. Until end of April 2016 he was Chief Scientific Officer and President of R&D at Shanghai CP Guojian Pharmaceutical Co., a leading China-based biopharmaceutical company focusing on developing therapeutic antibodies to treat various diseases. Previously he was the Senior VP Biologics at Shanghai ChemPartner, where he established comprehensive biologics R&D capabilities. Before that he was a Volwiler Associate Fellow at Abbott laboratories, USA. Dr. Wu has extensive experience in engineering and development of therapeutic monoclonal antibodies. He is also the primary inventor of the DVD-Ig technology, a new bi-specific antibody platform for developing next generation biologics therapies. Dr. Wu received his Ph.D. degree from the University of Georgia in the US, and postdoctoral training at Harvard Medical School.
Follow Chengbin Wu:
About EpimAb Biotherapeutics: EpimAb Biotherapeutics is a privately owned biopharmaceutical R&D company.
Qixi Chen
CEO and Co-Founder of DeepRed Technologies
Chase Chen currently works as Chief Executive Officer and Co-founder of DeepRed Technologies. He is also a Chief Operating Officer at NProcessor Inc. and an Assistant To Chief Executive Officer of Prowealth Group.
Follow Qixi Chen:
About DeepRed Technologies: DeepRed Technologies develops applications in healthcare, energy, manufacturing, and artificial intelligence.
Aonghus Shortt
Founder and CEO of FoodMarble
Follow Aonghus Shortt:
About FoodMarble: We measure your digestion. Creators of the first personal digestive breath tester.
Dongcheng Yang
Founder and CEO of Maijing Gene
Dongcheng Yang is the founder and CEO of Maijing Gene.
Follow Dongcheng Yang:
About Maijing Gene: Maijing Gene is a gene detection technology company that specializes in R&D, production, and sales of molecular diagnostic products.
Fangmin Xie
Founder and CEO of Jianke
Follow Fangmin Xie:
About Jianke: Jianke is anonline B2C pharmacy and healthcare services platform.
Weiqi Liu
CEO of UNIMED
Follow Weiqi Liu:
About UNIMED: UNIMED provides integrated medical service models.
Ming Yan
CEO of Zhangshang Tangyi
Selected as a member of the 2016 “Thousand Talents Program” China Non-Public Medical Institutions Association of Endocrine Diabetes Professionals graduated from Cambridge University, worked for Johnson & Johnson Medical, Europe, Asia Pacific and China, and was awarded the annual sales champion of Greater China
Follow Ming Yan:
About Zhangshang Tangyi: Zhangshang Tangyi is a health management platform with a focus on diabetes.
Pyng Soon
CEO of Stocosil
Follow Pyng Soon:
About Stocosil: Stocosil is a pharmaceutical company delivering next generation products that treat the double-threat of hypertension and high cholesterol.
Xin Qiao
CEO and Co-Founder of Deepwise
Follow Xin Qiao:
About Deepwise: Deepwise is an artificial intelligence technology-based clinical imaging services provider.
Robert Braithwaite
Co-Founder & CEO of Luqa Pharmaceuticals
Robert Braithwaite is the Co-Founder & CEO at Luqa Pharmaceuticals
Follow Robert Braithwaite:
About Luqa Pharmaceuticals: Luqa Pharmaceuticals is a China-focused company.
Jiliang Ma
Founder and CEO of Modoo
Jiliang Ma is the founder and CEO of Modoo Technology. Most recently, Jiliang was a program manager at Mobvoi.
Follow Jiliang Ma:
About Modoo: Modoo Technology is a wearable for monitoring fetal health, measuring heart rate and baby movements.
Wenting Chen
Chairman and CEO of Laviana Pharma
Follow Wenting Chen:
About Laviana Pharma: Laviana Pharmatech specializes in providing process and manufacture outsourcing services for the pharmaceutical industry.
Jin Zhang
CEO and Founder of DXY
Jin Zhang is the Chief Executive Office and product director of DXY, a media platform focused on the areas of pharmaceuticals and life sciences. He joined DXY in 2008. Zhang began medical practice on the internet in 1999 and has a thorough understanding of web-based design in medical and health fields. He also worked at the first affiliated hospital of the College of Medicine of Zhejiang University. Zhang obtained his degree in medicine from Hsiang-Ya Medical College of Central South University in 2004.
Follow Jin Zhang:
About DXY: DXY is an online healthcare community for doctors, consumers, and healthcare organizations.
Libo Yang
CEO of Kanghui
Yang Libo is the CEO of Kang Hui Medical Instrument.
Follow Libo Yang:
About Kanghui: Kanghui is a professional medical instrument enterprise focused on the R&D and production of orthopedic devices.
Junling Liu
Co-Founder, Chairman and Chief Executive Officer of 111, Inc.
Junling Liu is the co-founder, Chairman and CEO of 111,Inc., a leading digital and mobile health group in China since 2015. Before 111,Inc., Junling Liu was the Co-Founder of online retailer Yihaodian, one of the most successful online retailers in China. Yihaodian was founded in 2008 and is now China’s largest on-line retailer. In November 2011, Deloitte recognized Yihaodian as the fastest growing company in the Asia Pacific Region. Yihaodian has since received capital investment from global retailing company Walmart. Before co-founding Yihaodian, Junling Liu was Co-President of Dell China and Hong Kong, and also held senior management positions with Avaya China, Avaya Asia Pacific and Lucent Technologies. Junling Liu has been named a Top 10 Financial Figure of the Year in China’s IT Industry in 2006, and a Top 10 Figure of the Year in the Computer World in 2007.
Follow Junling Liu:
About 111, Inc.: 111, Inc. operates as a digital and mobile healthcare platform.
Dr. Harsh Sethia
Founder & CEO of Meddibuddy
HARSH is a doctor, health education specialist and Meddibuddy company’s founder. He is very keen on high-tech medical industry can change. Although it is a medical worker, but the Internet platform for docking, he taught himself how to write computer programs. He also mastered the graphic design and Mandarin skills. Harsh doctors graduated from Southern Medical University, worked at the National University of Singapore (NUS), Medica Superspecialty hospitals and clinics Global Doctor worked.
Follow Dr. Harsh Sethia:
About Meddibuddy: Meddibuddy – Let us help you find World-class health services.
Tai-Sen Soong
CEO, Founder of Senhwa Biosciences
Dr. Soong is the President, and CEO of Senhwa, which he co-founded in 2012. Leveraging a breadth of operations experience spanning 30 years, he has executive responsibility for all of the internal operations. He also currently serves as Vice Chairman of CDIB Bioscience Venture Management (CBVM) . He was the former Head of the Life Science Investment Unit in the Overseas Business Department at CDIB since 1999. Prior to joining CDIB, he was the Managing Director of Imagen Venture Holdings, Singapore. While at his tenure at National University of Singapore, he successfully launched Singapore China Biotechnology Program to recruit scientists from China to assist biotechnology development in Singapore. He was also one of the first few employees of Taiwan′s Development Center for Bitoechnology (DCB). During the period of 1986 -1995, he established an R & D base for commercial application of biotechnology and promoted Taiwan′s biotechnology through product development and technology transfer. He is also founding members and Board Directors of HenKan Pharmaceuticals and Medtech Tronics, Inc. Dr. Soong received his Ph.D. degree in Biology from University of Illinois at Urbana-Champaign.
Follow Tai-Sen Soong:
About Senhwa Biosciences: Senhwa is a drug development company creating innovative therapies for cancer and related diseases.
Kai Wang
CEO & Founder of OrigiMed
Kai Wang is the CEO & Founder at OrigiMed.
Follow Kai Wang:
About OrigiMed: OrigiMed provides molecular diagnostic information for cancer patient.
Qiu Jia Lin
Founder and Chief Executive Officer of Weimai
Follow Qiu Jia Lin:
About Weimai: Weimai uses big data and artificial intelligence to digitize their healthcare service platform.
Yusheng Zhang
Founder & CEO of Apricot Forest
Yusheng Zhang is the founder and chief executive officer of Apricot Trees Information Technology, an entrepreneurial firm focused on the development of mobile tools for medical professionals. Zhang previously served in an American medical big data startup and a medical insurance group that is among the top 500 global corporations. Zhang holds master’s degrees in public health and business administration from Johns Hopkins University. He obtained a PhD in clinical medicine from Peking Union Medical College.
Follow Yusheng Zhang:
About Apricot Forest: Apricot Forest’s mobile app provides doctors with patient records
Liang Liang
CEO & Co-founder of Easyhin Technology
Liang Liang is the Co-founder & CEO at Easyhin Technology.
Follow Liang Liang:
About Easyhin Technology: Easyhin Technology is an mobile internet company on healthcare management of women and children.
HaoXiang Yi
CEO of Kether
Yi HaoXiang currently works as the Founder for Kether. A rookie in the domestic EEG field, a post-90s entrepreneur who graduated from Zhejiang University, once went to the University of California, Davis (UC Davis) to participate in laboratory research projects, began to develop commercial EEG acquisition technology and commercial promotion during the undergraduate period, graduated Previously obtained cooperation orders from China National Science and Technology Museum, Zhejiang Science and Technology Museum and other units.
Follow HaoXiang Yi:
About Kether: Kether is a designer and developer of brain monitoring device company.
Duojia Feng
CEO of Beijing Tiantan Biological Products
Duojia Feng is CEO at Beijing Tiantan Biological Products.
Follow Duojia Feng:
About Beijing Tiantan Biological Products: Beijing Tiantan Biological Products Corporation Limited specializes on the biopharmaceutical industry.
Ping Chen
CEO & Founder of Lianluo Smart Ltd.
Ping Chen is a Chief Executive Officer, Director of Lianluo Smart Limited (formely known Dehaier Medical Systems Limited). He was Chairman of the Board, Chief Executive Officer of Dehaier Medical Systems Ltd.
Follow Ping Chen:
About Lianluo Smart Ltd.: Lianluo Smart Ltd. engages in the development, manufacturing, marketing and distribution of medical products.
Yang Ling
President and Chief Executive Officer of Beijing Gene+ Technology
Doctor of Medicine, Associate Researcher, Master’s Tutor of Chinese Academy of Sciences, Member of Professional Committee of Health Risk Assessment and Control of Chinese Preventive Medicine Institute, engaged in R & D and clinical examination of gene health field for more than ten years, served as Head of Health Department of Huada, Shenzhen Huada Director of clinical examination center, general manager of Tianjin Huada, director of Shenzhen Municipal Key Laboratory of pathogen nucleic acid detection, director of Shenzhen Key Laboratory of Clinical Molecular Diagnosis, director of Tianjin Medical Genomics Engineering Center and director of Tianjin Key Laboratory of Enterprise , Has a wealth of clinical testing and company operating experience.
Follow Yang Ling:
About Beijing Gene+ Technology: Beijing Gene+, also known as Beijing Gene Plus, provides gene testing services for cancer prevention
Ligang Zhang
Founder, Chairman and CEO of iKang Healthcare Group
Zhang Ligang is the founder, Chairman and CEO of iKang Health Group, a provider of private preventive healthcare services in China. Ligang acquired ShanghaiMed Company Limited in 2003 and serves as of Chairman and CEO of the company. His past employers include Sohu, Elong and Shanghai Med Company Limited. Ligang attended Fudan University, Columbia University and Harvard University. He served as President and publisher of Harvard China Review.
Follow Ligang Zhang:
About iKang Healthcare Group: Ikang is a Chinese health management service agency providing personalized health-related services.
Chuan de La Hosseraye
Founder and CEO of AWB Health
Follow Chuan de La Hosseraye:
About AWB Health: AWB Health, one stop digital platform involving Nutrition, Medical, Fitness, Emotional well-being and Environment.
Xiangfei Chai
Founder & CEO of Huiyi Huiying
Obtained Postdoctoral fellow in Stanford University, doctor degree in medical physics major in Amsterdam University in Holland. He had studied and worked in the world top medical imaging organizations, such as cancer center of Stanford University, Holland cancer research center and radiology department in Leuven University. He has over 10 years experience on interdisciplinary scientific research and project in the field of Artificial Intelligence, image processing, and data analysis, with the good knowledge of the core technology of image segmentation, identification, analysis and deep learning algorithm. He has been honored “Top 30 AI Start-up entrepreneur” and “Best Youth Model”. Xiangfei Chai also was the the first term trainee of Qingteng University held by Tencent.
Follow Xiangfei Chai:
About Huiyi Huiying: Huiyi Huiying is an international cloud computing & AI tech that has created a digital medical imaging and tumor radiotherapy platform.
Jim Wu
Founder and CEO of Ark Biosciences
Follow Jim Wu:
About Ark Biosciences: Ark Biosciences is a biopharmaceutical company that is dedicated to the discovery and development
Mingyan Xu
CEO & Founder of HaploX Biotechnology
Follow Mingyan Xu:
About HaploX Biotechnology, Hypros: HaploX Biotechnology is a Shenzhen-based genetic sequencing company.
Ying Wu
CEO of blüüm
Ying Wu is the Chief Executive Officer of bluum.
Follow Ying Wu:
About blüüm: Blüüm is a health platform that offers augmented health services maximizing the quality of life at every stage.
Han Wei
Founder and CEO of Lefit
Follow Han Wei:
About Lefit: Lefit is a Hangzhou-based new concept fitness start-up gym operator.
Ryan Hua Zhang
CEO of Linkingmed
Dr. Ryan Zhang received his PhD training at the Netherlands Cancer Institute and obtained his BS degree from Southeast University. He has founded three companies before starting Linkingmed in 2016. Dr. Zhang has 8 patents and is involved in 6 research projects funded by provincial natural science funds, including Guangdong Natural Science Foundation (No. 2014A030313146), Guangdong Natural Science Foundation (2016A030313302), Sichuan Applied Basic Research Program (key project, No. 2018GZ0197). He has published 7 SCI papers and 8 international conference papers in peer-reviewed journals such as Radiotherapy & Oncology, Phys Med Biol, and Med Phys. He received the 2012 Best Clinical Research Award from the Dutch Cancer Forum, 2014 SIAM (Science and Applied Mathematics Association) Travel Grant.
Follow Ryan Hua Zhang:
About Linkingmed: Linkingmed is focused on establishing oncology data platform and medical data analysis.
Gang Qin
Founder & CEO of GeneQuantum Healthcare
Gang Qin, Ph.D. is Founder and Chief Executive Officer of GeneQuantum Healthcare.
Follow Gang Qin:
About GeneQuantum Healthcare: GeneQuantum Healthcare is a high-tech company that focuses on the research and development of innovative Bio-therapeutics.
Shana Penna
Founder & CEO of Inmogeia Technologies
Shana is an internationally focused entrepreneur creating technology that makes an impact. Her passion is stimulated by developments in global health technology trends that use emerging technologies like artificial intelligence, robotics, and blockchain. She has dedicated her career to finding the intersection between technology and transformational outcomes. Prior to founding Inmogeia Technologies, Shana was the cofounder of an assistive technology company, Puffin Innovations, which used AI and internet of things connectivity to empower those with severe disabilities. She received an MBA from the prestigious MIT Sloan dual degree program at Tsinghua University in Beijing China.
Follow Shana Penna:
About Inmogeia Technologies: Inmogeia Technologies is a digital platform empowering people to better manage their autoimmune diseases.
Ying Zhong
Executive Director and Chief Executive Officer of Jinxin Fertility
Follow Ying Zhong:
About Jinxin Fertility: Jinxin Fertility is a Chinese fertility services provider.
Lipson Roberta
President & CEO of Chindex International
Follow Lipson Roberta:
About Chindex International, United Family Healthcare: Chindex International, Inc. provides healthcare services in China.
Depeng Wang
CEO of GrandOmics
As a senior in the field of sequencing, he started the application of Sanger sequencing technology in 2000 and has been engaged in the application of next generation sequencing technology since 2007, including early incubation and promotion of NIPT, PGD/PGS, HLA typing, whole exome sequencing and so on. With the development of third-generation sequencing technology, he started sequencing services based on third-generation sequencing technology in 2012 and initiated and participated in the completion of the first near complete reference Chinese human genome“HuaXia1(HX1)” led by professor Wang kai and Su guohui. Since 2016, he has been engaged in research on Chinese structural variation data and participated in several major research projects based on third-generation sequencing technology.
Follow Depeng Wang:
About GrandOmics: Grandomics provides molecular diagnosis, research, and carrier screening for single gene diseases.
Yingqi Xu
Chief Executive Officer of Yidianling
Xu Yingqi has over a decade of work experience in the gaming, pharmaceutical and finance sectors. He joined an online gaming company named 5173 in 2003 and expanded the team from 20 to 3,000 employees, increasing the yearly GMV from US$3m to more than US$1.5bn. Xu then joined a pharmaceutical company named 818 in 2009, helping over 300 pharmacies go online. The company’s business grew 248% annually under his leadership. In 2003, Xu started financial services platform 658 that generated RMB1.3bn worth of transactions. In 2015, he went on to establish Yidianling, an online mental health consultancy.
Follow Yingqi Xu:
About Yidianling: Yidianling is an online psychological counselling platform that provides free questions and answers, psychological tests & expert services.
Gong Jianbo
CEO of Shandong Weigao Orthopedic Device Company
Gong Jianbo aged 47, was appointed as our Director on April 6, 2005 and redesignated as our executive Director on October 22, 2014. He is also the chief executive officer. Mr. Gong has over 20 years of experience in orthopedic implant industry in China. Mr. Gong joined our Group on April 6, 2005. He has been an executive director of Weigao Medical Polymer since March 2013 and the general manager of our Group since March 2005.
Follow Gong Jianbo:
About Shandong Weigao Orthopedic Device Company: Shandong Weigao Orthopedic Device Company is a medical device company in China specializing in the research and development, production.
Bing Wu
Founder, CEO of ChronoCloud
Follow Bing Wu:
About ChronoCloud: ChronoCloud is committed to people’s daily health management and disease prevention and control.
Xu Zhiyan
CEO of Liking Fit
Served as a domestic listed Internet company VP, has created a number of companies. In 2014, we launched “The Best Chef”, the nation’s largest private-owned home-improvement platform, completed Series B financing in 2015 and “Liking Fitness” in 2016.
Follow Xu Zhiyan:
About Liking Fit: Liking Fit is a Chinese franchise smart gym operator.
